The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•8 April 2026•

1 min read

Halozyme and Vertex Partner on Hypercon Technology for Enhanced Drug Delivery

Key Facts

1Halozyme Hypercon, a subsidiary of Halozyme Therapeutics, signed a licensing agreement with Vertex Pharmaceuticals for up to three drug targets.

2Vertex will pay an upfront fee of $15 million, with potential future milestone payments and royalties on net sales.

3The technology aims to hyperconcentrate drugs to enable smaller injection volumes and facilitate at-home administration.

Create Free Account

Halozyme Therapeutics (HALO) has announced a strategic licensing agreement between its subsidiary, Halozyme Hypercon, and Vertex Pharmaceuticals (VRTX). The deal grants Vertex access to Halozyme's innovative Hypercon technology for up to three specific drug targets. Under the terms of the agreement, Vertex will provide an upfront payment of $15 million, with eligibility for future milestone payments based on development and commercial success. Additionally, Halozyme is set to receive royalties on net sales of products utilizing the technology. The Hypercon technology is designed to hyperconcentrate biologics, enabling smaller injection volumes and facilitating at-home administration for patients. This partnership underscores the growing demand for advanced drug delivery systems that enhance patient convenience and treatment adherence.